Adaptimmune Therapeutics annual shares outstanding
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics Shares Outstanding History (ADAPY)
Adaptimmune Therapeutics reported 1.54B shares outstanding at the end of fiscal 2024.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 1.54B | 172.6M | +12.67% |
| 2023 | 2023-12-31 | 1.36B | 375.9M | +38.08% |
| 2022 | 2022-12-31 | 987.1M | 58.6M | +6.31% |
| 2021 | 2021-12-31 | 928.5M | −207,024 | −0.02% |
| 2020 | 2020-12-31 | 928.8M | 297.8M | +47.19% |
| 2019 | 2019-12-31 | 631.0M | 3.5M | +0.57% |
| 2018 | 2018-12-31 | 627.5M | 65.3M | +11.62% |
| 2017 | 2017-12-31 | 562.1M | 137.3M | +32.33% |
| 2016 | 2016-12-31 | 424.8M | 63,192 | +0.01% |
| 2015 · Dec 31 | 2015-12-31 | 424.7M | 0 | 0.00% |
| 2015 · Jun 30 | 2015-06-30 | 424.7M | — | — |
Adaptimmune Therapeutics quarterly shares outstanding
Q4.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 1.59B | 56.1M | +3.66% |
| Q1 2025 | 2025-03-31 | 1.55B | 14.1M | +0.92% |
| Q4 2024 | 2024-12-31 | 1.54B | 172.6M | +12.67% |
| Q3 2024 | 2024-09-30 | 1.53B | 172.6M | +12.68% |
| Q2 2024 | 2024-06-30 | 1.53B | 182.4M | +13.49% |
| Q1 2024 | 2024-03-31 | 1.53B | 539.3M | +54.27% |
| Q4 2023 | 2023-12-31 | 1.36B | 375.9M | +38.08% |
| Q3 2023 | 2023-09-30 | 1.36B | 378.9M | +38.55% |
| Q2 2023 | 2023-06-30 | 1.35B | 375.1M | +38.40% |
| Q1 2023 | 2023-03-31 | 993.7M | 52.8M | +5.62% |
| Q4 2022 | 2022-12-31 | 987.1M | 49.6M | +5.29% |
| Q3 2022 | 2022-09-30 | 982.7M | 45.7M | +4.87% |
| Q2 2022 | 2022-06-30 | 976.8M | 40.5M | +4.33% |
| Q1 2022 | 2022-03-31 | 940.9M | 8.0M | +0.86% |
| Q4 2021 | 2021-12-31 | 937.5M | 8.8M | +0.95% |
| Q3 2021 | 2021-09-30 | 937.0M | 8.5M | +0.92% |
| Q2 2021 | 2021-06-30 | 936.2M | 8.6M | +0.92% |
| Q1 2021 | 2021-03-31 | 932.8M | 152.3M | +19.51% |
| Q4 2020 | 2020-12-31 | 928.8M | 297.8M | +47.19% |
| Q3 2020 | 2020-09-30 | 928.5M | 297.6M | +47.16% |
| Q2 2020 | 2020-06-30 | 927.7M | 297.0M | +47.09% |
| Q1 2020 | 2020-03-31 | 780.5M | 152.2M | +24.23% |
| Q4 2019 | 2019-12-31 | 631.0M | 3.5M | +0.57% |
| Q3 2019 | 2019-09-30 | 631.0M | 3.7M | +0.59% |
| Q2 2019 | 2019-06-30 | 630.7M | 64.2M | +11.33% |
| Q1 2019 | 2019-03-31 | 628.3M | 63.4M | +11.23% |
| Q4 2018 | 2018-12-31 | 627.5M | 65.3M | +11.62% |
| Q3 2018 | 2018-09-30 | 627.2M | 65.1M | +11.58% |
| Q2 2018 | 2018-06-30 | 566.5M | 5.4M | +0.96% |
| Q1 2018 | 2018-03-31 | 564.9M | 45.9M | +8.84% |
| Q4 2017 | 2017-12-31 | 562.1M | 137.3M | +32.33% |
| Q3 2017 | 2017-09-30 | 562.1M | 137.4M | +32.35% |
| Q2 2017 | 2017-06-30 | 561.1M | 136.4M | +32.11% |
| Q1 2017 | 2017-03-31 | 519.0M | 94.3M | +22.19% |
| Q4 2016 | 2016-12-31 | 424.8M | 63,192 | +0.01% |
| Q3 2016 | 2016-09-30 | 424.7M | 0 | 0.00% |
| Q2 2016 | 2016-06-30 | 424.7M | — | — |
| Q1 2016 | 2016-03-31 | 424.7M | — | — |
| Q4 2015 | 2015-12-31 | 424.7M | — | — |
| Q4 2015 | 2015-06-30 | 424.7M | — | — |
Adaptimmune Therapeutics shares outstanding trends
Over the last five reported fiscal years, Adaptimmune Therapeutics's shares outstanding moved from 631.0M to 1.54B, a change of 904.7M. The latest reported quarter, Q2 2025, shows 1.59B.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptimmune Therapeutics filings at SEC.gov ↗